This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BEC2

Eli Lilly & Company

Drug Names(s): Mitumomab, IMC-BEC2

Description: BEC2 stimulates the ganglioside GD3 which, in turn, has the potential to stimulate an immune response against tumor cells expressing GD3.BEC2-mediated cancer immunotherapy was stimulated by a manuscript published in the July 1991 issue of the Journal of Clinical Investigation in which Memorial Sloan-Kettering Cancer Center researchers successfully targeted GD3 with BEC2 in rabbit models, stimulating a biologically relevant immune response. Such a tumor vaccine approach is designed to prevent or delay tumor recurrences.

Deal Structure: Merck KGaA and ImClone partnered in 1990 to develop BEC2. ImClone and Merck KGaA will co-promote BEC2 in the U.S. while Merck KGaA has all rights outside the U.S.

In November 2008 Eli Lilly completed the acquisition of ImClone Systems.

Partners: Merck KGaA


BEC2 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug